Phase I clinical and pharmacokinetic study of PM01183 (a tetrahydroisoquinoline, Lurbinectedin) in combination with gemcitabine in patients with advanced solid tumors

Overview of attention for article published in Investigational New Drugs, November 2016

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (85th percentile)
Good Attention Score compared to outputs of the same age and source (75th percentile)

Mentioned by

blogs: 1 blog
twitter: 1 X user

patent: 3 patents

Citations

dimensions_citation: 22 Dimensions

Readers on

mendeley: 37 Mendeley

Summary Blogs X Patents Dimensions citations

So far, Altmetric has seen 3 patents that reference this research output.

METHODS OF TREATING SMALL CELL LUNG CANCER WITH LURBINECTEDIN FORMULATIONS

Application WO-2021228414-A1

World Intellectual Property Organisation (WIPO)

METHODS OF TREATING SMALL CELL LUNG CANCER WITH LURBINECTEDIN FORMULATIONS

Application WO-2021098992-A1

World Intellectual Property Organisation (WIPO)

LURBINECTEDIN IN THE TREATMENT OF MALIGNANT MESOTHELIOMA

Application WO-2021043949-A1

World Intellectual Property Organisation (WIPO)